Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.47 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595640 | 1.00 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPEPDTP53 | |
| SCHEMBL595642 | 1.00 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPEPDTP53 | |
| SCHEMBL30142964 | 0.96 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPEPDTP53 | |
| SCHEMBL12987462 | 0.96 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPEPDTP53 | |
| SCHEMBL13011624 | 0.96 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPEPDTP53 | |
| SCHEMBL30553087 | 0.96 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPEPDTP53 | |
| SCHEMBL1296411 | 0.96 | PPM1B (0.47) | PPM1BPTPN1PPP1CCPEPDTP53 | |
| SCHEMBL9683498 | 0.92 | PPM1B (0.50) | PPM1BPTPN1PPP1CC | |
| SCHEMBL9683505 | 0.92 | PPM1B (0.50) | PPM1BPTPN1PPP1CC | |
| SCHEMBL12988317 | 0.92 | PPM1B (0.50) | PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3341353-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017035271-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-8153644-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153644-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153644-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | RDX, C3AR1, LPXN | PPM1B 3442/4885PTPN1 2153/4885PPP1CC 4142/4885 |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | PPM1B 1251/4885PTPN1 2416/4885PPP1CC 3444/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | PPM1B 1251/4885PTPN1 2416/4885PPP1CC 3444/4885 |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C3AR1, LPXN | PPM1B 3442/4885PTPN1 2153/4885PPP1CC 4142/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | PPM1B 1251/4885PTPN1 2416/4885PPP1CC 3444/4885 |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | PPM1B 3645/4885PTPN1 2437/4885PPP1CC 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.